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BACKGROUND: Oral epithelial dysplasia (OED) is a histologically detectable lesion that may progress to carcinoma but there are no
accurate markers that predict progression. This study examined the development of carcinoma from oral dysplastic lesions, and the
association between abnormal DNA content and progression to carcinoma.
METHODS: Epithelial dysplasias from the Oral Pathology Diagnostic Service were matched against the Ontario Cancer Registry
database to identify cases that progressed to carcinoma. A case–control study was conducted to compare DNA image cytometry of
dysplasias that progressed with those that have not progressed. For a subset of the progressed dysplasias, DNA content of the
carcinoma was also analysed.
RESULTS: A total of 8% of epithelial dysplasias progressed to carcinoma after 6–131 months. In all, 28 of 99 dysplasias showed
abnormal DNA content by image cytometry. In multivariate analysis of time to progression, abnormal DNA content was a significant
predictor with hazard ratio of 3.3 (95% confidence interval: 1.5–7.4) corrected for site and grade of dysplasia. Analysis of sequential
samples of dysplasia and carcinoma suggested that epithelial cell populations with grossly abnormal DNA content were transient
intermediates during oral cancer development.
CONCLUSIONS: Abnormal DNA content is a significant biomarker of a subset of OED that progress to carcinoma.
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Oral squamous carcinoma develops through multiple steps of
accumulation of genetic and epigenetic alterations, which implies
that elimination of pre-invasive, precursor lesions can reduce the
morbidity and mortality of this malignant disease (Califano et al,
1996; Reibel, 2003). The best-known precursor lesion is epithelial
dysplasia, which is histologically detectable and often presents
clinically as white or red mucosal patches called leukoplakia and
erythroplakia (Warnakulasuriya et al, 2007). However, only a
minority of epithelial dysplasias progress to carcinoma, whereas
other dysplastic lesions remain unchanged for years or resolve
over time (Napier and Speight, 2008). Currently, assessment of risk
of carcinoma is based on clinical and histological features, but
there is no available marker that can accurately predict the
behaviour of an individual dysplastic lesion so that appropriate
treatment can be rendered to prevent carcinoma (Reibel, 2003).
Histological grading is subjective, with intra- and inter-observer
variability (Warnakulasuriya et al, 2008). Computer-assisted
analysis of histological appearance has been reported to increase
prognostic value but it still relies on morphological changes to
predict behaviour of the lesion (Guillaud et al, 2008).
Several molecular aberrations have been studied as predictive
markers for progression of oral epithelial dysplasia (OED) to
carcinoma. These include immunohistochemical staining for the
p53 tumour suppressor protein (Cruz et al, 1998), overexpression
of matrix metalloproteinase mRNA (Jordan et al, 2004), loss of
heterozygosity (LOH) at specific chromosomal loci (Mao et al,
1996; Rosin et al, 2000), promoter methylation of the p16 tumour
suppressor gene (Hall et al, 2008) and alterations in microRNA
expression (Cervigne et al, 2009). These markers have not yet been
widely adopted for assessment of risk of progression of OED.
The development of oral squamous carcinoma is a complex
multistep process that may involve escape from senescence, loss of
p53 and p16 function, and genetic instability (Hunter et al, 2005).
We hypothesise that changes in cellular DNA content, or DNA
aneuploidy, is a critical event during oral squamous carcinoma
development. Studies of cervical carcinogenesis and Barrett’s
oesophagus have shown that genetic instability occurred during
malignant progression (Galipeau et al, 1996; Rabinovitch et al,
2001; Olaharski et al, 2006). A recent study of OED showed that
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progressed than among lesions that did not progress (Torres-
Rendon et al, 2009).
In this study, we reviewed a large series of OED from an
outpatient oral biopsy service and identified the cases that
progressed from dysplasia to carcinoma by linkage of the biopsy
database with the cancer registry. A retrospective case–control
study was conducted to study the association between abnormal
DNA content and the clinical outcome of whether the lesion
progressed to carcinoma, or not progressed after a reasonable
follow-up period. We showed that DNA content analysis by image
cytometry can be successfully applied to most archival, formalin-
fixed, paraffin-embedded tissue specimens. Distinctive patterns of
DNA content distribution could be recognised and provided
information of biological and clinical significance.
MATERIALS AND METHODS
Collection of dysplasia and carcinoma cases
This retrospective study has been approved by the Research Ethics
Boards of the University of Toronto (protocol reference number
21571) and Sunnybrook Health Sciences Centre (project identifica-
tion number 363–2008). The files of the Oral Pathology Diagnostic
Service (OPDS) at the Faculty of Dentistry, University of Toronto,
were searched for all cases coded as epithelial dysplasia for the
years 1993–2002 inclusive. The list of dysplasia was matched
against the oral cancer database of the Ontario Cancer Registry,
which collects data on all cases of cancer diagnosed in the
province. The match produced a sub-list of cases of OED that were
associated with subsequent carcinoma at the same anatomical site
or a contiguous site. Examples of contiguous sites included tongue
and floor of the mouth, and mandibular mucosa and floor of the
mouth. The majority of the diagnoses of oral carcinoma were made
in different hospitals across the province, including Sunnybrook
Health Science Centre (SHSC). In a small number of cases, the oral
carcinoma diagnosis was made at the OPDS at the University of
Toronto. We were able to retrieve the paraffin-embedded samples
of oral carcinoma from SHSC and OPDS for analyses in
conjunction with the preceding dysplastic lesion.
Cases of OED that did not produce a match from the oral cancer
database would include epithelial dysplasias that have not
progressed to oral cancer. It was also possible that the patient
has moved out of province and developed oral carcinoma
elsewhere. Therefore, we sought confirmation that the patient
has not moved out of province and was alive with no evidence of
oral cancer, from the clinician who submitted the biopsy of the
dysplastic lesion. We identified a group of ‘control’ patients whose
dysplastic lesion has not progressed after a minimum follow-up
period of 5 years. The control group was chosen to match the
group of patients with ‘progressed’ dysplasia for age and sex. Five
cases of oral squamous papilloma, which is a hyperplastic lesion of
stratified squamous epithelium, were taken from the OPDS files
and used as reference cases for DNA content analysis.
Analysis of DNA content
Isolation of nuclei from paraffin-embedded tissue Between three
and six thick sections (50mm) were cut from each paraffin block,
depending on the size of tissue in the block. Thick sections were
needed to avoid partial nuclei (Hedley, 1994). If necessary, areas of
skeletal muscle or submucosal tissue were trimmed away from
the paraffin block before sections were cut. Sections were
de-paraffinised in xylene and rehydrated in graded ethanol to
distilled water. The rehydrated tissues were digested with type
XXIV proteinase (2ml at 0.5mgml
–1 in PBS, P8038; Sigma-
Aldrich, Oakville, ON, Canada) in a 371C water bath for 90min
with vigorous shaking. Digestion was stopped by adding an equal
volume of cold PBS, and undigested tissue was separated from the
suspension of nuclei by filtering through a 70mm mesh (BD Falcon
352350, VWR Mississauga, ON, Canada). The nuclei were gently
spun down by centrifugation and the pellet was resuspended in
cold PBS (Diwakar et al, 2005). The concentration of nuclei was
estimated by counting a sample in a hemocytometer and adjusted
to B300–400 nuclei per ml. A monolayer of the nuclei was made
by cytospin (Thermo Shandon Cytospin 4 cytocentrifuge, Fisher
Scientific, Ottawa, ON, Canada), air-dried and sent for DNA
staining and image cytometry (Figure 1).
DNA image cytometry Image cytometric analysis for DNA
content of samples of dysplasia and carcinoma were performed
by an accredited quantitative cytology laboratory (Perceptronix
Medical Inc, Vancouver, BC, Canada). Cases of oral squamous
papilloma from the OPDS were used as reference. All samples were
analysed by laboratory personnel with no knowledge of the
diagnoses. The cytospin preparations of nuclei were stained by the
Feulgen–thionin method of stochiometric DNA staining (Clear2C
staining kit, Perceptronix Medical Inc). Image cytometric analysis
was performed using an automated image cytometer (registered
in vitro diagnostic medical device ClearCyte, Perceptronix Medical
Inc (Health Canada License Number 7062; CE Mark Registration
Number IE/CA01/R/IV/0773/5048)) that was operated within the
requirements given in the ESACP consensus report (Haroske et al,
2001). The image cytometer consisted of the following compo-
nents: microscope with automated programmable XYZ stage and
controller (AxioPlan2, Carl Zeiss Jena GmbH, Thornwood, NY,
USA), automated programmable slide loader (Ludl Electronic
Products Ltd, Hawthorne, NY, USA), high-resolution monochrome
CCD camera (QICAM, Qimaging, Vancouver, BC, Canada),
computer with high-resolution monitor and image analysis soft-
ware. The system used a  20 objective (numerical aperture 0.75)
with a  0.63 projection lens, resulting in spatial resolution of
0.54mm and effective pixel size of 0.37 0.37mm
2. The image
analysis software calculated features characterising the size, shape
and distribution of optical density within the objects (Doudkine
et al, 1995). These features were used by classification algorithms
trained to recognise isolated epithelial nuclei and leukocytes from
debris, overlapping cells and objects out of focus. Normal
epithelial cells present within each sample were used as internal
control. The DNA index (DI) (normalised DNA content) was used
to classify epithelial nuclei into four groups: DI of 0.85–1.15, DI of
1.15–1.7, DI of 1.7–2.3 and DI 42.3, corresponding to diploid
nuclei in G0/G1, S phase, G2/M phase or tetraploid nuclei, and
aneuploid nuclei, respectively. A gallery of imaged objects was
presented for visual review by a cytopathologist who confirmed
that the right population of cells was used for normalisation and
that the coefficient of variation of the diploid peak was o5%, and
then verified objects in the non-diploid groups. A frequency
histogram of DI and a report of the analysis were generated for
each sample (Figure 1). Typically, 1000–5000 epithelial nuclei
could be analysed in a cytospin preparation. A small number of
cases with o500 nuclei yielded histograms of poor quality and
were excluded from further analyses.
Classification of DNA content/criteria for abnormal DNA
histogram The criteria for classification of DNA content as
‘abnormal’ or ‘no abnormality detected’ were based on published
studies of OED and carcinoma (Diwakar et al, 2005; Klanrit et al,
2007; Torres-Rendon et al, 2009). Samples were considered to have
no detectable abnormality if the histogram showed one peak of
nuclei with DI of 0.85–1.15 (diploid nuclei in G0 or G1), fewer than
1% of nuclei had DI 42.3, and there were fewer than 10% of the
nuclei with DI of 1.7–2.3 (nuclei in G2/M). All five cases of
squamous papilloma clearly fit these three criteria.
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Sections of 4mm thickness were cut onto coated slides (number
00211, Surgipath, Winnipeg, MB, Canada). Sections were
de-paraffinised in xylene, and hydrated in graded ethanol to
distilled water. Endogenous peroxidase was blocked by treatment
with 3% hydrogen peroxide in distilled water for 10min. For
antigen retrieval, slides were immersed and heated in 10mM citrate
buffer (pH 6) for 10min at 1201C in a pressurised chamber
(Milestone Srl, Esbe Scientific, Toronto, ON, Canada) and then
allowed to cool for 10min. Sections were incubated with 5%
normal horse serum in TBST (Tris-buffered saline with 0.1%
Tween) for 30min, followed by incubation at 41C overnight with
monoclonal antibody to p53 (clone DO-7, DAKO M7001,
Mississauga, ON, Canada) at 1/100 dilution in normal serum-
TBST. The primary antibody was followed by biotinylated
horse anti-mouse IgG and avidin–biotin–peroxidase conjugate
(Vectastain Elite ABC Kit, Vector Labs, Burlington, ON, Canada).
Each incubation was followed by washes in TBST. The target
antigen was visualised by treatment with Nova Red substrate
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Figure 1 DNA content analysis of biopsy specimens. Top panel, left: 50-mm thick paraffin sections before de-paraffinisation and rehydration; right:
cytospin preparation of nuclei after Feulgen–thionin staining. The bottom panel shows an example of DNA content analysis of a dysplasia sample with
abnormal DNA content; left: image gallery of aneuploid nuclei (DNA index (DI) X2.3), showing that each event with abnormal DNA content corresponds
with a single nucleus and is not an artefact of clumped nuclei or debris; right: scatter plot of area of nucleus and DI, where nuclei were colour-coded
according to DI, shown above the corresponding DNA histogram. CV, coefficient of variation; Ent, entropy of histogram data; Mn, mean.
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Staining was assessed on a semiquantitative scale: 0, no staining;
1, weak staining in o10% of epithelial nuclei; 2, moderate/strong
staining in 10–50% of epithelial nuclei; 3, moderate/strong
staining in 450% of epithelial nuclei.
Statistical analyses
Statistical analyses were performed with SAS (version 9.1, SAS
Institute, Cary, NC, USA). Data were summarised using descriptive
statistics. The exact Cochran–Armitage trend test was performed to
investigate the association between histological grade of dysplasia and
finding of concurrent or subsequent carcinoma and the association
between grade of dysplasia and abnormal DNA content. The
proportions of abnormal DNA content among three site groups
were compared using Fisher’s exact test. Our primary outcome is time
to progression to carcinoma from diagnosis of dysplasia. Time
to progression to carcinoma for dysplastic lesions with or without
abnormality of DNA content was examined in Kaplan–Meier plots.
Log-rank test was used to compare the time to progression between
the two groups. Time to progression to carcinoma for lesions with
different grades of dysplasia was also examined similarly. Multivariate
analysis of time to progression was performed using Cox propor-
tional hazard model with abnormal DNA content, grade of dysplasia
and site included as predictors in the model. Differences were
considered statistically significant if Po0.05.
RESULTS
Progression of dysplasia to carcinoma
A search of the files of the OPDS for the years 1993–2002 inclusive
for cases diagnosed as epithelial dysplasia yielded 1477 biopsies
from 1313 patients. The distribution of the biopsies by grade of
dysplasia and oral site are shown in Table 1. A match of the list
of dysplasia against the Ontario Cancer Registry for Oral Cancer
led to identification of 114 cases of dysplasia from 82 patients
that were followed by verrucous carcinoma or squamous cell
carcinoma at the same anatomical site or a contiguous site, with an
interval of at least 6 months between dysplasia and carcinoma.
These cases were considered as progression of dysplasia to
carcinoma. In addition, there were 44 cases of dysplasia from
40 patients that were associated with carcinoma at the same
anatomical site within 6 months, considered as dysplasia
concurrent with carcinoma. The finding of subsequent carcinoma
and concurrent carcinoma by histological grade of dysplasia and
by oral site are shown in Table 1. There was a significant asso-
ciation between grade of dysplasia and occurrence of carcinoma
(either subsequent or concurrent), with Po0.0001 using Cochran–
Armitage trend test.
The interval between dysplasia and carcinoma for the 82
progressed patients varied from 6 months to 131 months with a
median of 44 months. For patients who had multiple biopsies of
dysplasia preceding carcinoma, the interval was calculated from
the latest dysplasia before carcinoma. For 59 of the 82 patients
(72%) who progressed, carcinoma developed within 5 years of the
latest dysplasia.
DNA content analysis of dysplasia samples
Selection of ‘progressed’ and ‘have not progressed’ samples for DNA
content analysis Among the 82 patients who progressed from
dysplasia to carcinoma, there were 49 patients for whom a paraffin
block of dysplasia could be retrieved from storage, with sufficient
tissue for successful analysis of DNA content. The reasons for
inability to analyse DNA content included tissue depleted in
previous research projects, block unavailable because it was
returned to the primary institution, and insufficient tissue in the
block to yield enough epithelial nuclei for DNA analysis.
Among patients who did not match the Oral Cancer database, we
identified 50 patients for whom we were able to confirm with the
clinician who submitted the biopsy that the patient was alive with
no evidence of oral cancer after a follow-up period of 5 years or
more. The requirement of at least 5 years of follow-up was based
on the finding that the majority of patients with progressed
dysplasias developed carcinoma within 5 years of the dysplasia.
Table 2 shows the characteristics of the two patient groups for
whom DNA content analysis was carried out.
Results of DNA content analysis DNA content analysis was
performed for 99 cases of dysplasia as listed in Table 2, and the
DNA histograms were categorised as ‘abnormal’ or ‘no abnorm-
ality detected’ according to the criteria described in the Materials
and Methods section. The five cases of squamous papilloma that
were used as reference cases had no detectable abnormality in
DNA content (Figure 2A). In all, 28 of the 99 dysplasia cases
showed abnormal DNA content. Twenty-two of these dysplasias
(79%) have progressed to carcinoma, and six have not progressed.
There was a predominance of tongue lesions among dysplasias
with abnormal DNA content, as 21 of the 28 cases with abnormal
DNA were from the tongue. The histological grade of the
dysplasias with abnormal DNA content ranged from mild
(7 cases) to moderate (13 cases) to severe (8 cases).
Table 1 Association between dysplasia and carcinoma, by histological grade and oral site
Number of biopsies
diagnosed as dysplasia
Number of dysplasia with
subsequent carcinoma (%)
a
Number of dysplasia concurrent
with carcinoma (%)
b
Number with subsequent
or concurrent carcinoma (%)
All histological grades 1477 114 (7.7) 44 (3.0) 158 (10.7)
Mild 959 37 (3.9) 10 (1.0) 47 (4.9)
Moderate 326 34 (10.4) 9 (2.8) 43 (13.2)
Severe 149 35 (23.5) 14 (9.4) 49 (32.9)
Carcinoma in situ 43 8 (18.6) 11 (25.6) 19 (44.2)
All oral sites 1477 114 (7.8) 44 (3.0) 158 (10.7)
Tongue 271 36 (13.3) 10 (3.7) 46 (17.0)
Floor of mouth 329 39 (11.9) 15 (4.6) 54 (16.4)
Buccal mucosa 216 10 (4.6) 4 (1.9) 14 (6.5)
Gingiva 254 19 (7.5) 7 (2.8) 26 (10.2)
Palate, tonsillar pillar 224 7 (3.1) 3 (1.3) 10 (4.5)
Lip 114 1 (0.9) 4 (3.5) 5 (4.4)
Site not stated 69 2 1 3
aCarcinoma followed dysplasia by X6 months.
bDysplasia and carcinoma occurred within 6 months.
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content as seen in the DNA histogram had a large peak with DI
between 1.7 and 2.3 (peritetraploid peak), along with aneuploid
nuclei with DI 42.3 (Figure 2B). The peritetraploid peak greatly
exceeded the peak formed by diploid cells in G2 and M phases of
the cell cycle, which occupied a similar range of DI. Other cases
show an aneuploid peak with DI between 1.15 and 1.7, along with
aneuploid nuclei with DI 42.3 (Figure 2C). For descriptive
purposes, we referred to the abnormal peak with DI between 1.15
and 1.7 as a hyperdiploid peak.
Seventy-one dysplasias were classified as having no detected
abnormality in DNA content. Twenty-seven of these (38%) have
progressed to carcinoma (Figure 2D).
Association between abnormal DNA content and clinicopatho-
logical features There was an association between grade of
dysplasia and abnormal DNA content. Of 50 patients with mild
dysplasia, 7 (14%) had abnormal DNA content, compared with 13
of 34 (38%) for moderate dysplasia, and 8 of 15 (53%) for severe
dysplasia/carcinoma in situ. The trend was statistically significant
with P¼0.001 (exact Cochran–Armitage trend test).
To explore whether there was a higher frequency of abnormal
DNA content among dysplasias from the tongue, we regrouped the
sites of dysplasia into three groups: tongue, floor of mouth and
others (buccal mucosa, gingiva–alveolar mucosa, soft palate–
tonsillar pillar). Abnormal DNA content was found for 21 of 41
(51%) dysplasias from the tongue, 4 of 25 (16%) from floor of
mouth and 3 of 33 (9%) for the others. The difference in frequency
could not be explained by a higher proportion of moderate or
severe dysplasia/carcinoma in situ in tongue lesions. Among
tongue dysplasias, 56% were mild, 34% were moderate and 10%
severe/carcinoma in situ. For floor of mouth dysplasias, 52% were
mild, 32% moderate and 16% severe/carcinoma in situ. For buccal
mucosa, gingiva–alveolar mucosa, soft palate–tonsillar pillar
combined, 42% were mild dysplasias, 36% moderate and 21%
severe/carcinoma in situ. The association between site of dysplasia
and abnormal DNA content was statistically significant with
Po0.0001 using Fisher’s exact test.
We compared the two groups of patients with abnormal DNA
histogram (n¼28) and normal DNA histogram (n¼71), with
respect to time to progression to carcinoma. The median time to
progression for patients with abnormal DNA histogram was 49
months (95% confidence interval (CI): 34–86 months), compared
with 130 months (95% CI: 84–131 months) for patients with
no detected abnormality on the DNA histogram. The time to
progression plots are shown in Figure 3. The difference in time to
progression between the two groups was statistically significant
with P¼0.0001 using log-rank test. All patients who did not
progress to carcinoma were followed up for at least 5 years. The
proportion of patients who were cancer free at 5 years were 75%
(95% CI: 65–85%) for those with normal DNA histogram and 44%
for those with abnormal DNA histogram (95% CI: 29–68%).
We also examined the time to progression to carcinoma
according to grade of dysplasia, as mild (n¼50), moderate
(n¼34) and severe/carcinoma in situ (n¼15). The last two groups
were combined because of the small number of dysplasias in these
groups. The median time to progression were 111 months (95% CI:
83–131 months), 87 months (95% CI: 71 months, upper limit not
reached) and 56 months (95% CI: 32–84 months), respectively. The
differences in time to progression to carcinoma among the three
different grades were statistically significant (P¼0.02, Figure 4).
To determine whether abnormal DNA content was a significant
predictor of time to progression, corrected for the effect of site and
grade, we performed multivariate analysis using Cox proportional
hazard model. Abnormal DNA content was a significant predictor
with P¼0.003. The hazard ratio was 3.3 (95% CI: 1.5–7.4) for
abnormal DNA content vs normal DNA content.
Sequential samples of dysplasia and carcinoma
For 15 of the dysplasias that progressed to carcinoma, it was possible
to analyse the DNA content of sequential samples of dysplasia and
carcinoma. Nine of these 15 dysplasias showed an abnormal DNA
content. For 6 of these 9 cases, the subsequent carcinoma showed a
similar pattern of DNA content abnormality as the corresponding
dysplasia. However, the percentage of nuclei with abnormal DNA
content was clearly lower in the carcinoma than in the preceding
dysplasia in three cases (Figure 5A and B), whereas in the other three
cases, the percentages remained similar. In three cases of dysplasia
with abnormal DNA content, the large peritetraploid peak could not
be detected in the subsequent carcinoma and the percentage of
nuclei with DI 42.3 was also lower.
For five of six cases of dysplasia in which no abnormality was
detected in DNA content, the carcinoma that followed also showed
no significant abnormality in the DNA histogram. One of these
carcinomas recurred as a neck mass, which showed a
large peritetraploid peak in the DNA histogram (Figure 5C–E).
In one case of dysplasia with no abnormality detected in DNA
content, the patient developed carcinoma 131 months following
the biopsy of dysplasia. Owing to the extent of the clinical white
lesion, the carcinoma was treated with radiation and tumour tissue
was not available for DNA content analysis. At 50 months
following the first carcinoma, the patient developed a carcinoma
at the anterior aspect of the white patch. The second carcinoma
showed a large peritetraploid peak, along with many aneuploid
nuclei with DI 42.3.
Immunohistochemical staining for p53
We studied the expression of p53 protein in the samples of
dysplasia and carcinoma where there was sufficient tissue to allow
Table 2 Characteristics of the two groups of dysplasia used for DNA
content analysis
Progressed
to cancer
Did not
progress
N 49 50
Age (years)
Mean (s.d.) 60 (13) 55 (14)
a
Median (range) 60 (32–83) 55 (17–79)
Sex
F (%) 22 (45) 25 (50)
M (%) 27 (55) 25 (50)
Grade
Mild (%) 21 (43) 29 (58)
Moderate (%) 16 (33) 18 (36)
Severe (%) 11 (22) 3 (6)
Carcinoma in situ (%) 1 (2) 0 (0)
Site
Tongue (%) 22 (45) 19 (38)
Floor of mouth (%) 14 (29) 11 (22)
Buccal mucosa (%) 5 (10) 8 (16)
Gingiva/alveolar mucosa (%) 4 (8) 9 (18)
Soft palate/tonsillar pillar (%) 4 (8) 3 (6)
Interval between dysplasia and
carcinoma, median (range) in months
49 (6–131) N/A
Duration of follow-up, median
(range) in months
N/A 80 (59–122)
Abnormal DNA content (%) 22 (45) 6 (12)
Abbreviations: F¼female; M¼male; N/A¼not applicable.
aThe age of four patients
in this group was not available.
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used for DNA content analysis (77 of 99 cases stained). The
purpose was to determine if p53 immunohistochemical staining
could be related to abnormal DNA content. p53 staining was
assessed on a semiquantitative scale from 0 to 3, as described in
the Materials and Methods. For comparison of staining among
groups of dysplasia, grades 0 and 1 staining were combined as
‘weak’ staining, whereas grades 2 and 3 were combined as ‘strong’
staining. Among 27 cases of dysplasia with abnormal DNA content,
12 cases (44%) showed strong p53 staining and 15 (56%) cases
showed weak staining (Table 3, Figure 6A and C). Among 50 cases
with no detected abnormality in DNA content, 19 (38%) exhibited
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Figure 2 DNA histogram and haematoxylin–eosin stained section for representative cases. (A) Squamous papilloma used as reference in this study.
No abnormality was detected in the DNA histogram. The large peak consisted of nuclei in G0/G1 phases of cell cycle and the small peak consisted of nuclei
in G2/M phases. (B) Moderate dysplasia of the tongue that progressed to carcinoma after 41 months. Altogether, 45% of nuclei had a DNA index (DI)
between 1.7 and 2.3 (peritetraploid peak) and 1.3% of the nuclei were aneuploid (DI X2.3). (C) Severe dysplasia of the floor of the mouth that progressed
to carcinoma after 6 months. There was an abnormal peak with DI between 1.15 and 1.7 (21% of nuclei, hyperdiploid peak), 16% of nuclei in the
peritetraploid region and 5.7% of nuclei were aneuploid. (D) Carcinoma in situ of the floor of mouth that progressed to carcinoma in 61 months.
No abnormality was detected in the DNA histogram. Each bar in the photomicrographs represents 200mm.
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sstrong staining and 31 (62%) were weak. The results did not
demonstrate a higher proportion of strong p53 staining among
cases with abnormal DNA content compared with cases with no
abnormality in DNA content (44 vs 38%).
For 11 cases of sequential dysplasia and carcinoma, tissue was
available for immunohistochemical staining for p53 for both
dysplasia and carcinoma. In 10 of the 11 cases there was
concordance of staining results for the dysplasia and subsequent
carcinoma, supporting the notion that the carcinoma may have
developed from the dysplasia (Figure 6).
DISCUSSION
The progression of epithelial dysplasia to carcinoma is not well
understood at present. Longitudinal studies are needed to
determine the frequency of progression of epithelial dysplasia to
carcinoma and to identify biological markers that can predict
disease progression, but relatively few such studies have been
carried out (Schepman et al, 1998; Reibel, 2003; Holmstrup et al,
2006). A recent series of reports of long-term follow-up of oral
leukoplakia and erythroplakia and the value of DNA content
analysis as a prognostic marker have been retracted because of
inaccuracies in the data (Curfman et al, 2006). Our retrospective
study provided information on progression to carcinoma in a large
cohort of patients who had one or more biopsies of epithelial
dysplasia in an outpatient biopsy service. We showed that 8% of
lesions (114 biopsies out of 1477) diagnosed as epithelial dysplasia
progressed to carcinoma, after an interval of 6 months to 131
months. This represents the lower limit of the frequency of
progression to carcinoma, because more carcinomas will likely
develop with longer follow-up. There was a trend towards more
cases of subsequent or concurrent carcinoma with increasing
histological grade of dysplasia, but we noted that 37 of the 114
cases of subsequent carcinoma were found with mild dysplasia
(Table 1). For these cases, histological assessment was not an
accurate indicator of the risk of progression. There is therefore a
need for biological markers to aid in the prediction of progression
of dysplasia to carcinoma.
The data on progression of dysplasia to carcinoma should also
be considered in the context of incidence of oral cancer and the
proportion of oral cancer cases that are preceded by dysplastic
lesions. Retrospective analysis of the files of the OPDS at the
University of Toronto from 1993 to 2002 revealed 1477 cases of
dysplasia, of which 158 cases were found to be associated with
subsequent or concurrent carcinoma (Table 1). During the same
10-year period, the Oral Pathology Service at the University of
Western Ontario received 1378 biopsies that were diagnosed as
dysplasia or carcinoma in situ (T Daley, University of Western
Ontario, London, ON, Canada, personal communication). In
addition, we estimated that a similar number of biopsies of OEDs
would be sent to pathology laboratories in hospitals across the
province of Ontario, giving a total of approximately 4200 cases
of OED in Ontario. Using the proportion of 158 of 1477 cases
of dysplasia that were associated with oral cancer, we estimated
that there were 450 cases of dysplasia that were associated with
subsequent or concurrent carcinoma. For comparison, the Ontario
Cancer Registry had 5120 cases of oral cancer in this 10-year
period. The proportion of oral cancer cases that were preceded by
a dysplastic lesion was likely higher than these figures would
suggest. As dysplastic oral lesions are typically asymptomatic, they
may remain undiagnosed in patients who do not have the benefit
of regular oral examinations accompanied by biopsy of suspicious
lesions. Our data suggested that improvements in the diagnosis
and risk assessment of OED would assist the early diagnosis of oral
cancer.
We showed that archival, formalin-fixed, paraffin-embedded
biopsy specimens that have been in storage for as long as 15 years
can be used successfully for DNA content analysis by image
cytometry. Factors that limited the use of archival specimens
included small size of the biopsy and inability to produce an
adequate preparation of nuclei for image cytometry, but these
affected only a minority of the cases we wished to study.
The ability to use archival dysplasia specimens allowed us to
relate the findings of DNA content analysis to long-term clinical
outcome regarding progression to carcinoma.
Thick tissue sections (50mm) were used for preparation of
nuclei, to decrease the likelihood of partial nuclei that would cause
an artefactually lowered DNA content. It was not possible to
perform microdissection of these thick sections to isolate epithelial
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Figure 3 Kaplan–Meier plot of time to progression for patients with
normal (n¼71) vs abnormal (n¼28) DNA histogram. Each ‘J’ indicates a
censor, when the patient was last examined without evidence of
progression to cancer. The difference in time to progression between
the two groups was statistically significant (P¼0.0001 by log-rank test).
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Figure 4 Kaplan–Meier plot of time to progression for patients with
mild dysplasia (n¼50), moderate dysplasia (n¼34) and severe dysplasia/
carcinoma in situ (n¼15). Each ‘J’ indicates a censor, when the patient
was last examined without evidence of progression to cancer. The
differences in time to progression among the different grades were
statistically significant (P¼0.02, log-rank test).
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snuclei from the nuclei of fibroblasts, endothelial cells and other
non-epithelial cells. We divided nuclei into four groups of DI
values and used previously published criteria to classify the DNA
histogram as ‘abnormal’ or ‘no abnormality detected’ (see
Materials and Methods).
We found a strong association between abnormal DNA content
and progression to carcinoma. Of the 28 cases of dysplasia with
abnormal DNA content, 22 were associated with subsequent
carcinoma. Among the six patients with dysplasias that showed
abnormal DNA content but have not progressed to carcinoma,
one has a persistent dysplastic lesion, and three patients had
re-excision of the dysplastic lesion followed by resolution. The
remaining two patients’ lesions resolved after the first biopsy.
Owing to the limited amount of clinical information that was
available in our retrospective study, we could not analyse in detail
the effect of surgical excision on progression of epithelial
dysplasia, but we considered it possible that differences in surgical
treatment could be a confounding factor in the association
between abnormal DNA content and progression to carcinoma.
In a multivariate analysis of DNA content, site and grade of
dysplasia as predictors of time to progression, abnormal DNA
content was a significant predictor with a hazard ratio of 3.3
DNA ploidy histogram: all islolated epithelial nuclei
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Figure 5 DNA histograms for sequential dysplasia and carcinoma. (A) Severe dysplasia of the tongue showing an abnormal peritetraploid peak with 52%
of the nuclei and 4.5% of nuclei in the aneuploid region. (B) Carcinoma that developed 20 months later, with 17% of nuclei in a peritetraploid peak and 2.2%
of nuclei in the aneuploid region. (C) Mild dysplasia of the tongue with no detected abnormality in the DNA histogram. (D) Carcinoma that developed
33 months later, with no detected abnormality in the DNA histogram. (E) Recurrent carcinoma in the neck that developed 12 months after treatment of
the primary carcinoma, showing 22% of nuclei in a peritetraploid peak and 3.3% of nuclei in the aneuploid region.
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s(95% CI: 1.5–7.4). A prospective, long-term follow-up study of a
large series of OED from multiple centres that collects information
on the surgical treatment rendered for the dysplastic lesion, with
conventional histological assessment and DNA content analysis by
image cytometry, should provide further information on abnormal
DNA content as a marker for progression to carcinoma. This line
of investigation should improve our ability to identify and treat a
subset of high-risk dysplastic lesions.
Allelic loss or LOH at microsatellite markers have been found in
longitudinal studies to indicate the risk of progression of
dysplastic oral lesions to carcinoma (Partridge et al, 2000; Rosin
et al, 2000). In one study, LOH at 3p and/or 9p, with or without
additional losses on 4q, 8p, 11q or 17p was predictive of
progression. The proportion of dysplasias that did not progress
at 5 years after diagnosis was 98% for cases without LOH at 3p and
9p, 63% for cases with LOH at 3p and/or 9p, and 53% for cases
with LOH at 3p and/or 9p plus any of the other four arms (Rosin
et al, 2000). In this study of DNA ploidy, the proportion who were
cancer free at 5 years were 75% for cases with normal DNA
histogram and 44% for cases with abnormal DNA histogram (see
Results). It should be noted that the LOH study differed from our
study in that many of the patients were followed up for o5 years.
Neither LOH nor DNA ploidy analysis could identify all cases of
dysplasia that progressed to carcinoma. Prospective studies using
both LOH and DNA ploidy would be useful to determine whether
these markers identify the same or complementary subsets of
dysplasias that progress to carcinoma.
Our finding of a strong association between abnormal DNA
content and progression to carcinoma agreed with a previous
study of DNA ploidy analysis and malignant progression of OEDs,
where 14 of 19 aneuploid dysplasias progressed to carcinoma
(Torres-Rendon et al, 2009). In addition, we demonstrated for the
first time that progressed dysplasias were often characterised by a
high percentage of peritetraploid nuclei along with a smaller
number of aneuploid nuclei (Figure 2B). Interestingly, our study of
sequential cases of dysplasia and carcinoma showed that the large
aberrations in DNA content seen in dysplasias often appeared
reduced in the subsequent carcinomas (Figure 5A and B). The
large peritetraploid peak that was seen in many DNA histograms of
progressed dysplasias was rarely found in carcinomas. We were
careful to select areas of carcinoma with a high carcinoma/stroma
ratio for preparation of nuclei, so that the reduction in severity of
DNA content abnormality was unlikely to be an artefact of dilution
by stromal cells. Our observations suggested that epithelial cells
with large aberrations in DNA content, which predominated in the
dysplasia, have been replaced in the subsequent carcinoma by cells
with less severe aberrations in DNA content. Studies of cell lines
have shown that tetraploid cell populations are unstable inter-
mediates in the development of aneuploidy (Ganem et al, 2007;
Storchova and Kuffer, 2008). DNA content analyses of sequential
biopsies of Barrett’s oesophagus have shown that G2/tetraploid
populations were intermediates in the progression to aneuploidy
and carcinoma and that they were associated with loss of p53
(Galipeau et al, 1996; Maley et al, 2004). Studies of precancerous
cervical lesions showed that tetraploidy occurred during the early
stages of cervical carcinogenesis and preceded the development of
aneuploidy (Olaharski et al, 2006). Although our study was limited
by the small number of sequential samples and possible
heterogeneity of DNA ploidy status within large lesions of
carcinoma (Diwakar et al, 2005), our findings support the
hypothesis that epithelial cell populations with grossly abnormal
DNA content act as intermediates in the multistep process of oral
carcinoma development. Further studies are needed to confirm
this hypothesis. Dysplastic lesions with abnormal DNA content are
at risk for progression to carcinoma, but they may also be
susceptible to control by targeted therapy such as reactivation or
augmentation of the DNA damage response (Storchova and Kuffer,
2008).
Table 3 Results of p53 staining according to DNA content and
progression to carcinoma
Number of cases
with strong p53
staining (%)
Number of cases
with none or weak
p53 staining (%)
Abnormal DNA content – 27 cases 12 (44) 15 (56)
Progressed to carcinoma 11 11
Have not progressed to
carcinoma
14
No abnormality detected in DNA
content – 50 cases
19 (38) 31 (62)
Progressed to carcinoma 11 6
Have not progressed to
carcinoma
82 5
Figure 6 Immunohistochemical staining for p53 protein in sequential dysplasia and carcinoma, showing concordance of staining results for the dysplasia
and subsequent carcinoma in two representative cases (counterstained with haematoxylin). (A) Moderate dysplasia of tongue showing moderate to strong
staining of 10–50% of epithelial nuclei (grade 2 staining). (B) Carcinoma that developed 86 months later showing moderate to strong staining in 410% of
epithelial nuclei (grade 2–3 staining). (C) Severe dysplasia of the tongue that showed no p53 staining. (D) Carcinoma that developed 20 months later also
showed no p53 staining. Each bar in the photomicrographs represents 100mm.
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associated with loss of p53 function. In studies of Barrett’s
oesophagus, increase in the fraction of G2/tetraploid cells was
associated with 17p allelic loss and p53 mutation (Galipeau et al,
1996). Increased immunohistochemical staining for p53 protein
was reported to be associated with increased genetic instability in
pre-neoplastic epithelium as measured by chromosomal in situ
hybridisation (Shin et al, 2001). We therefore studied the
expression of p53 protein by immunohistochemical staining, in
parallel with DNA content analysis in 77 of the 99 cases of
dysplasia. The immunohistochemical staining did not demonstrate
an association between increased p53 staining and abnormal DNA
content. Although increased p53 staining is often indicative of a
mis-sense mutation in p53 resulting in a stabilised mutant protein,
there are other types of p53 mutation, which lead to decreased or
loss of staining. Sequencing of the p53 gene and analysis of
deletion at the 17p locus would provide more definitive informa-
tion on p53 function, but these investigations were not possible in
our study due to insufficient tissue.
In all, 27 of the 49 progressed dysplasias in our study did not
show abnormality in DNA content by image cytometry (Table 2).
The DNA content histogram for these lesions appeared similar to
the reference cases of squamous papilloma (Figure 2D). In our
limited analysis of sequential dysplasia and carcinoma, five of six
cases of progressed dysplasias with no abnormality in DNA
content were associated with carcinoma with a similar DNA
histogram (Figure 5C and D). This suggested that progression of
dysplasia to carcinoma may not involve gross aberrations of DNA
content, which are demonstrated by DNA image cytometry. Thus,
there are at least two subsets of progressing dysplasias that differ
in genetic characteristics. Combined analyses of OED that include
DNA image cytometry and multiple genetic and epigenetic
markers will be needed to identify a panel of biomarkers that
will accurately predict the risk of carcinoma.
CONCLUSIONS
Our retrospective study of OED showed that at least 8% of these
lesions were associated with subsequent carcinoma. A subset
(45%) of dysplasias which ultimately progressed were charac-
terised by abnormal DNA content by DNA image cytometry. There
was an association between abnormal DNA content and increased
risk of progression of epithelial dysplasia to carcinoma. There is a
need to identify additional biomarkers besides abnormal DNA
content in order to accurately predict the progression from
dysplasia to carcinoma.
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